ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

Начало・Списък с акции・Sanofi SA
Search

Sanofi SA

Затворен

СекторЗдравеопазване

76.89 -0.91

Купи

Обновена цена 22.05.2026 г., 15:29 ч. UTC

КупиПродай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

76.87

Максимум

76.99

Ключови измерители

By Trading Economics

Приходи

-394M

1.6B

Продажби

-12B

11B

P/E

Средно за сектора

18.773

49.701

EPS

1.88

Марж на печалбата

14.354

Служители

74,846

EBITDA

1.5B

2.7B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+23.85% upside

Дивиденти

By Dow Jones

Следващи печалби

30.07.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-9.6B

89B

Предишно отваряне

77.8

Предишно затваряне

76.89

Настроения в новините

By Acuity

44%

56%

126 / 345 Класиране в Healthcare

Sanofi SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.04.2026 г., 09:03 ч. UTC

Печалби

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

DJ

Прочетени

29.04.2026 г., 05:27 ч. UTC

Печалби

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

DJ

Прочетени

23.04.2026 г., 06:12 ч. UTC

Печалби

Sanofi Posts Higher Sales Amid Leadership Transition

DJ

Прочетени

7.05.2026 г., 06:47 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

DJ

Прочетени

1.05.2026 г., 06:14 ч. UTC

Придобивния, сливания и поглъщания

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

DJ

Прочетени

1.05.2026 г., 06:13 ч. UTC

Придобивния, сливания и поглъщания

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

DJ

Прочетени

1.05.2026 г., 06:12 ч. UTC

Придобивния, сливания и поглъщания

Santander UK Financed Deal From Existing Cash Resources

DJ

Прочетени

1.05.2026 г., 06:08 ч. UTC

Придобивния, сливания и поглъщания

Santander UK Announced Key Terms of Deal July 2025

DJ

Прочетени

1.05.2026 г., 06:03 ч. UTC

Придобивния, сливания и поглъщания

Santander UK Buys TSB Banking for GBP2.65B

DJ

Прочетени

1.05.2026 г., 06:02 ч. UTC

Придобивния, сливания и поглъщания

Santander UK Buys TSB Banking Group

DJ

Прочетени

29.04.2026 г., 12:01 ч. UTC

Печалби

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

DJ

Прочетени

29.04.2026 г., 06:27 ч. UTC

Пазарно говорене
Печалби

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

DJ

Прочетени

29.04.2026 г., 04:55 ч. UTC

Печалби

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

DJ

Прочетени

29.04.2026 г., 04:55 ч. UTC

Печалби

Santander 1Q Loan Loss Provisions EUR3.225B

DJ

Прочетени

29.04.2026 г., 04:54 ч. UTC

Печалби

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

DJ

Прочетени

29.04.2026 г., 04:54 ч. UTC

Печалби

Santander 1Q Operating Expenses EUR6.48B

DJ

Прочетени

29.04.2026 г., 04:52 ч. UTC

Печалби

Santander Backs 2028 View

DJ

Прочетени

29.04.2026 г., 04:52 ч. UTC

Печалби

Santander Backs 2026 View

DJ

Прочетени

29.04.2026 г., 04:52 ч. UTC

Печалби

Santander 1Q Underlying RoTE 15.2%

DJ

Прочетени

29.04.2026 г., 04:51 ч. UTC

Печалби

Santander End-1Q CET1 Ratio 14.4%

DJ

Прочетени

29.04.2026 г., 04:51 ч. UTC

Печалби

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

DJ

Прочетени

29.04.2026 г., 04:51 ч. UTC

Печалби

Santander 1Q Net Interest Income EUR11.02B

DJ

Прочетени

29.04.2026 г., 04:50 ч. UTC

Печалби

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

DJ

Прочетени

29.04.2026 г., 04:50 ч. UTC

Печалби

Santander 1Q Underlying Pft EUR3.56B

DJ

Прочетени

29.04.2026 г., 04:49 ч. UTC

Печалби

Santander 1Q Net Pft EUR5.455B

DJ

Прочетени

29.04.2026 г., 04:49 ч. UTC

Печалби

Analysts Saw Santander 1Q Rev EUR15.00B

DJ

Прочетени

29.04.2026 г., 04:49 ч. UTC

Печалби

Santander 1Q Rev EUR15.14B

DJ

Прочетени

27.04.2026 г., 09:32 ч. UTC

Пазарно говорене
Печалби

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

DJ

Прочетени

27.04.2026 г., 09:19 ч. UTC

Пазарно говорене

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

DJ

Прочетени

23.04.2026 г., 05:34 ч. UTC

Печалби

Sanofi: 2026 Expectations Are at Constant Exchange Rates

DJ

Прочетени

Сравнение с други в отрасъла

Ценова промяна

Sanofi SA Прогноза

Ценова цел

By TipRanks

23.85% нагоре

12-месечна прогноза

Среден 95.22 EUR  23.85%

Висок 107 EUR

Нисък 85 EUR

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Sanofi SA през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

9 ratings

4

Купи

5

Задържане

0

Продай

Според 9 анализатори, дали борсови рейтинги на Sanofi SA през последните 3 месеца.

Настроение

By Acuity

126 / 345 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Други акции от сектора

ARGX

Argenx SE

701

↓-0.82%

SHL.DE

Siemens Healthineers AG

34.58

↑ +0.26%

FRE

Fresenius SE & Co KGaA

38.84

↓-2.92%

PHIA

Koninklijke Philips NV

23.42

↑ +0.95%

FME

Fresenius Medical Care AG

37.3

↓-4.04%
help-icon Live chat